{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:52:30Z","timestamp":1777002750826,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10384-023-01016-4","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T05:01:43Z","timestamp":1691125303000},"page":"699-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-4541","authenticated-orcid":false,"given":"Islam Y.","family":"Swaify","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haytham E.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania A.","family":"El Essawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareem B.","family":"Elessawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362:726\u201338.","journal-title":"N Engl J Med"},{"key":"1016_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RW, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104\u201316.","journal-title":"Nat Rev Endocrinol"},{"key":"1016_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40265-018-1045-9","volume":"79","author":"N Genere","year":"2019","unstructured":"Genere N, Stan MN. Current and emerging treatment strategies for Graves\u2019 orbitopathy. Drugs. 2019;79:109\u201324.","journal-title":"Drugs"},{"key":"1016_CR4","first-page":"69","volume":"15","author":"A Bagheri","year":"2020","unstructured":"Bagheri A, Abbaszadeh M, Yazdani S. Intraorbital steroid injection for active thyroid ophthalmopathy. J Ophthalmic Vis Res. 2020;15:69\u201379.","journal-title":"J Ophthalmic Vis Res"},{"key":"1016_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1755-3768.2008.01171.x","volume":"87","author":"M Bordaberry","year":"2009","unstructured":"Bordaberry M, Marques DL, Pereira-Lima JC, Marcon IM, Schmid H. Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves\u2019 ophthalmopathy. Acta Ophthalmol. 2009;87:58\u201364.","journal-title":"Acta Ophthalmol"},{"key":"1016_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","volume":"88","author":"R Ebner","year":"2004","unstructured":"Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88:1380\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1016_CR7","first-page":"345","volume":"88","author":"A Poonyathalang","year":"2005","unstructured":"Poonyathalang A, Preechawat P, Charoenkul W, Tangtrakul P. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J Med Assoc Thai. 2005;88:345\u20139.","journal-title":"J Med Assoc Thai"},{"key":"1016_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1442-9071.2010.02332.x","volume":"38","author":"AA Alkawas","year":"2010","unstructured":"Alkawas AA, Hussein AM, Shahien EA. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol. 2010;38:692\u20137.","journal-title":"Clin Exp Ophthalmol"},{"key":"1016_CR9","first-page":"422","volume":"6","author":"E Rivera-Grana","year":"2015","unstructured":"Rivera-Grana E, Lin P, Suhler EB, Rosenbaum JT. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015;6:422.","journal-title":"J Clin Exp Ophthalmol"},{"key":"1016_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/128903","volume":"2014","author":"D Strianese","year":"2014","unstructured":"Strianese D, Iuliano A, Ferrara M, Comune C, Baronissi I, Napolitano P, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014: 128903.","journal-title":"J Ophthalmol"},{"key":"1016_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/IOP.0000000000001279","volume":"35","author":"K-L Yong","year":"2019","unstructured":"Yong K-L, Chng C-L, Sie NM, Lang S, Yang M, Looi A, et al. Methotrexate as an adjuvant in severe thyroid eye disease: does it really work as a steroid-sparing agent? Ophthalmic Plast Reconstr Surg. 2019;35:369\u201373.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1016_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcjo.2017.07.009","volume":"53","author":"A Rubinov","year":"2018","unstructured":"Rubinov A, Zommer H, Aghazadeh H, Weis E. Role of methotrexate in thyroid-related orbitopathy. Can J Ophthalmol. 2018;53:34\u20138.","journal-title":"Can J Ophthalmol"},{"key":"1016_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","volume":"55","author":"AJ Dickinson","year":"2001","unstructured":"Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 2001;55:283\u2013303.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1016_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje.1.02230","volume":"155","author":"W Wiersinga","year":"2006","unstructured":"Wiersinga W, Perros P, Kahaly G, Mourits M, Baldeschi L, Boboridis K, et al. Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387\u20139.","journal-title":"Eur J Endocrinol"},{"key":"1016_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","volume":"10","author":"P Cipriani","year":"2014","unstructured":"Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519\u201330.","journal-title":"Expert Rev Clin Immunol"},{"key":"1016_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14310\/horm.2002.1155","volume":"1","author":"L Bartalena","year":"2002","unstructured":"Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of graves\u2019 ophthalmopathy. Hormones (Athens). 2002;1:76\u201390.","journal-title":"Hormones (Athens)"},{"key":"1016_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1678495","volume":"2016","author":"HEDM Khalil","year":"2016","unstructured":"Khalil HEDM, El Gendy HA, Youssef HAR, Haroun HE, Gheita TA, Bakir HM. The effectiveness of intraocular methotrexate in the treatment of posterior uveitis in Beh\u00e7et\u2019s disease patients compared to retrobulbar steroids injection. J Ophthalmol. 2016;2016: 1678495.","journal-title":"J Ophthalmol"},{"key":"1016_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000293","volume":"4","author":"JD Benner","year":"2019","unstructured":"Benner JD, Dao D, Butler JW, Hamill KI. Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ Open Ophthalmol. 2019;4: e000293.","journal-title":"BMJ Open Ophthalmol"},{"key":"1016_CR19","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0161-6420(02)01125-9","volume":"109","author":"JR Smith","year":"2002","unstructured":"Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709\u201316.","journal-title":"Ophthalmology"},{"key":"1016_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/ijdvl.IJDVL_73_16","volume":"84","author":"J Mittal","year":"2018","unstructured":"Mittal J, Mahajan B. Intramatricial injections for nail psoriasis: an open-label comparative study of triamcinolone, methotrexate, and cyclosporine. Indian J Dermatol Venereol Leprol. 2018;84:419\u201323.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1016_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4274\/atfm.43534","volume":"71","author":"P Ustuner","year":"2018","unstructured":"Ustuner P, Balevi A, Ozdemir M. The comparison of the efficacy and safety of intralesional triamcinolone acetonide and methotrexate injections for the treatment of fingernail psoriasis. J Ankara Univ Fac Med. 2018;71:145\u201351.","journal-title":"J Ankara Univ Fac Med"},{"key":"1016_CR22","first-page":"1063","volume":"18","author":"C Carriere","year":"2020","unstructured":"Carriere C, Baier S, Campana LG, Puviani M, Eisendle K. Palliative intralesional tumescent methotrexate for recurrent locally advanced periocular cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges. 2020;18:1063\u20136.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1016_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14404","volume":"34","author":"T Searle","year":"2021","unstructured":"Searle T, Ali FR, Al-Niaimi F. Intralesional methotrexate in dermatology: diverse indications and practical considerations. Dermatol Ther. 2021;34: e14404.","journal-title":"Dermatol Ther"},{"key":"1016_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00417-012-2153-y","volume":"251","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Rim THT, Jang SY, Kim CY, Shin DY, Lee EJ, et al. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefes Arch Clin Exp Ophthalmol. 2013;251:261\u201370.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1016_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcjo.2011.12.005","volume":"47","author":"D Xu","year":"2012","unstructured":"Xu D, Liu Y, Xu H, Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol. 2012;47:34\u201341.","journal-title":"Can J Ophthalmol"},{"key":"1016_CR26","first-page":"173","volume":"4","author":"V Yakopson","year":"2015","unstructured":"Yakopson V, Carrasco J, Sharma P, Rabinowitz M, Stefanyszyn M. Effect of intraorbital steroid injections on intraocular pressure in thyroid eye disease. J Thyroid Disord Ther. 2015;4:173.","journal-title":"J Thyroid Disord Ther"},{"key":"1016_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.eye.6702933","volume":"22","author":"E Chee","year":"2008","unstructured":"Chee E, Chee S. Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye. 2008;22:311\u20135.","journal-title":"Eye"},{"key":"1016_CR28","first-page":"2031","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang Y, Du B, Yang M, Zhu Y, He W. Peribulbar injection of glucocorticoids for thyroid-associated ophthalmopathy and factors affecting therapeutic effectiveness: a retrospective cohort study of 386 cases. Exp Ther Med. 2020;20:2031\u20138.","journal-title":"Exp Ther Med"},{"key":"1016_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000328630","volume":"47","author":"MR Razeghinejad","year":"2012","unstructured":"Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47:66\u201380.","journal-title":"Ophthalmic Res"},{"key":"1016_CR30","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2165\/00003495-200666130-00003","volume":"66","author":"SP Modjtahedi","year":"2006","unstructured":"Modjtahedi SP, Modjtahedi BS, Mansury AM, Selva D, Douglas RS, Goldberg RA, et al. Pharmacological treatments for thyroid eye disease. Drugs. 2006;66:1685\u2013700.","journal-title":"Drugs"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01016-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-023-01016-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01016-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:17:34Z","timestamp":1700201854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-023-01016-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1007\/s10384-023-01016-4","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I. Y. Swaify, None; H. E. Nasr, None; R. A. El Essawy, None; K. B. Elessawy, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}